Urticaria is a common, heterogeneous group of disorders with a large variety of underlying causes. It is characterized by the appearance of fleeting wheals, which each last 1--24 hours and/or angioedema lasting up to 72 hours. This paper summarizes the *EAACI/GA*^2^*LEN/EDF/WAO guidelines* from 2009[@R1; @R2] for an outline of the diagnosis and treatment of the disease. Currently, these are the only international guidelines available. These guidelines are the result of a consensus reached during a panel discussion at the 3rd International Consensus Meeting on Urticaria, *Urticaria 2008*, a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the EU-funded network of excellence, the Global Allergy and Asthma European Network (GA[@R2]LEN), the European Dermatology Forum (EDF), and the World Allergy Organization (WAO).

CLASSIFICATION OF URTICARIA ON THE BASIS OF ITS DURATION, FREQUENCY, AND CAUSES {#s1}
===============================================================================

The spectrum of clinical manifestations of different urticaria subtypes is very wide. Additionally, 2 or more different subtypes of urticaria can coexist in any given patient. [Table 1](#T1){ref-type="table"} presents a classification for clinical use.

###### 

Assessment of Disease Activity in Urticaria Patients
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Another important factor the new guidelines point out is assessing disease activity. Where physical triggers are implicated an exact measurement of the intensity of the eliciting factor can be made, for example, the temperature and duration of application in cold urticaria or pressure, and the duration of application until provocation of lesions in delayed pressure urticaria. For nonphysical acute and chronic urticaria, assessing disease activity is more complex. The guidelines propose using scales from 0 to 3. This simple scoring system ([Table 1](#T1){ref-type="table"}) is based on the assessment of key urticaria symptoms (wheals and pruritus). It is also suitable for evaluation of disease activity by urticaria patients and their treating physicians and it has been validated.[@R3]

As urticaria symptoms frequently change in intensity during the course of a day, overall disease activity is best measured by advising patients to document 24-hour selfevaluation scores for several days.

DIAGNOSIS OF URTICARIA {#s2}
======================

Because of the heterogeneity of urticaria and its many subtypes, guidelines for diagnosis might start with a routine patient evaluation, which should comprise a thorough history and physical examination, and the ruling out of severe systemic disease by basic laboratory tests. Specific provocation and laboratory tests should be carried out on an individualized basis on the basis of the suspected cause.

Of all the diagnostic procedures, the most important is to obtain a thorough history including all possible eliciting factors and significant aspects of the nature of the urticaria. Questions suggested by the guidelines are summarized in [Table 2](#T2){ref-type="table"}.

The second step is physical examination of the patient. This should include a test for dermographism. Subsequent diagnostic steps will depend on the nature of the urticaria subtype, as summarized in [Table 3](#T3){ref-type="table"}.

###### 

Suggested Questions
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###### 

Recommended Diagnostic Tests in Frequent Urticaria Subtypes
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TREATMENT OF URTICARIA {#s3}
======================

Omission of Eliciting Drugs {#s3-1}
---------------------------

Common drugs eliciting and aggravating chronic spontaneous urticaria include nonsteroidal anti-inflammatory drugs and angiotensin-converting enzyme inhibitors.[@R1; @R2] If drugs are suspected to cause or aggravate urticaria, they should be omitted or substituted appropriately.

Avoidance of Physical and Other Stimuli in Inducible Urticaria {#s3-2}
--------------------------------------------------------------

In patients suffering from inducible urticaria such as cholinergic urticaria, solar urticaria, or cold urticaria, the avoidance of the trigger should be attempted as much as possible.

Treatment of Infectious Agents {#s3-3}
------------------------------

In some cases of chronic spontaneous urticaria eradication of infections, such as *H. pylori*, bowel parasites and bacterial infections of the nasopharynx, have shown to provide a benefit in the management of the disease.[@R1; @R2; @R4; @R5] However, the eradication of intestinal candida is no longer believed to be of benefit. In addition chronic inflammatory processes such as gastritis, esophageal reflux disease and inflammations of the bile duct and gall bladder are now believed to be potential causative factors and should be managed accordingly.[@R2; @R6]

Dietary Modifications {#s3-4}
---------------------

If IgE-mediated food allergy has been identified as a trigger of chronic spontaneous urticaria, the specific allergen should be avoided as much as possible. This should clear the symptoms within 24 to 48 hours. Pseudoallergens can also elicit or aggravate chronic spontaneous urticaria but, in contrast to Typ-I allergens, need to be avoided for at least 3 to 6 months, to provide any benefit.

Symptomatic Treatment {#s3-5}
---------------------

The aim of the symptomatic therapy is to provide complete symptom relief. In general a stepwise approach is followed as illustrated in [Figure 1](#F1){ref-type="fig"}.[@R2]
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Nonsedating antihistamines have a very good evidence for efficacy, a very good safety profile and are low in cost.Increasing the dose of the second generation antihistamines is recommended because of a good safety profile, good evidence of efficacy, and low cost. Although the third treatment step is supported by the benefit of a good safety profile and low to medium-low cost, there is no or insufficient evidence for its efficacy in high quality RCTs. Corticosteroids should only be used in the treatment of acute urticaria or acute flares of chronic spontaneous urticaria. Their long-term use should be avoided outside specialist clinics. In patients with severe urticaria refractory to any of the above measures, ciclosporin can be used as it has an effect on mast-cell mediator release and prevents basophil histamin release. However, because of its medium-high costs, moderate safety, and moderate level of evidence of efficacy, its benefits need to be carefully balanced against the disadvantages. Another option is the use of Omalizumab (anti-IgE) in some cases of chronic spontaneous urticaria, cholinergic-, cold-, or solar urticaria. Its high cost and low level of evidence of efficacy should be carefully considered before introducing the medication. Furthermore, many other treatments have been proposed like dapsone, sulfasalazine, methotrexat, IVIG, interferon, and plasmapharesis but only been tested in uncontrolled trials or case studies and further studies are required to evaluate their effects. [Table 4](#T4){ref-type="table"} illustrates the evidence for commonly used drugs.
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Modified From EAACI/GA²LEN/EDF/WAO Guideline: Management of Urticaria
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SUMMARY {#s4}
=======

The new guidelines for urticaria give clear recommendations, on diagnosis and treatment. Further RCTs are required to provide the best possible treatment to patients, who do not respond to first-or second line-treatments.
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